Sorafenib-induced destructive thyroiditis.
Iavarone
Massimo
M
Perrino
Michela
M
Viganò
Mauro
M
Beck-Peccoz
Paolo
P
Fugazzola
Laura
L
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000601:surgery; D002908:Chronic Disease; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007457:Iodine Radioisotopes; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011241:Prednisone / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib; D013667:Technetium; D013966:Thyroiditis / Q000139:chemically induced / Q000175:diagnosis*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D013667:Technetium; D011433:Propranolol; D000077157:Sorafenib; D011241:Prednisone